1,789 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Acquired by Vienna Asset Management LLC

Vienna Asset Management LLC bought a new position in shares of 10x Genomics, Inc. (NASDAQ:TXGGet Rating) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,789 shares of the company’s stock, valued at approximately $266,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of TXG. Morgan Stanley lifted its holdings in 10x Genomics by 40.4% during the 3rd quarter. Morgan Stanley now owns 6,075,112 shares of the company’s stock worth $884,415,000 after buying an additional 1,747,269 shares during the last quarter. D1 Capital Partners L.P. acquired a new position in 10x Genomics in the 4th quarter valued at about $239,081,000. Baillie Gifford & Co. increased its position in 10x Genomics by 24.1% in the 4th quarter. Baillie Gifford & Co. now owns 6,878,377 shares of the company’s stock valued at $1,024,603,000 after acquiring an additional 1,335,752 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in 10x Genomics in the 4th quarter valued at about $111,655,000. Finally, Marshall Wace LLP acquired a new position in 10x Genomics during the 3rd quarter worth approximately $43,288,000. 76.25% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have issued reports on TXG shares. Cowen dropped their target price on 10x Genomics from $205.00 to $145.00 in a research report on Thursday, February 17th. Citigroup lowered their price target on 10x Genomics from $150.00 to $100.00 in a report on Thursday, May 5th. The Goldman Sachs Group lowered their price target on 10x Genomics from $95.00 to $85.00 and set a “neutral” rating on the stock in a report on Wednesday, April 13th. Finally, Zacks Investment Research upgraded 10x Genomics from a “sell” rating to a “hold” rating in a report on Thursday, February 17th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $128.57.

TXG stock traded down $4.04 on Tuesday, reaching $45.72. The company had a trading volume of 1,031,356 shares, compared to its average volume of 1,404,164. 10x Genomics, Inc. has a 1 year low of $36.76 and a 1 year high of $208.99. The company has a market cap of $5.16 billion, a P/E ratio of -57.87 and a beta of 1.92. The company’s fifty day moving average is $60.30 and its 200 day moving average is $96.61.

10x Genomics (NASDAQ:TXGGet Rating) last issued its quarterly earnings results on Wednesday, May 4th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). 10x Genomics had a negative return on equity of 11.10% and a negative net margin of 17.85%. The business had revenue of $114.50 million for the quarter, compared to analysts’ expectations of $113.33 million. During the same period in the prior year, the company earned ($0.11) EPS. The company’s revenue for the quarter was up 8.2% compared to the same quarter last year. As a group, equities analysts anticipate that 10x Genomics, Inc. will post -0.91 EPS for the current year.

10x Genomics Company Profile (Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Further Reading

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXGGet Rating).

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.